Biotech Values

[ghmm]

Nektar's presentation of 214 at SITC they talked about combining with BOTH anti PD-1 & CTLA4. If I heard correctly they said the doses in the models were < 1/10th of the dose used in monotherapy. Don't know much about TRIL's compound but I imagine at such low doses the safety may become less of an obstacle (Nektar 214 doesn't appear to have cross tox with Checkpoint in limited human data thus far). Here is the slide on the 3 agents